HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,229,808 | +15.7% | 189,262 | +9.2% | 0.00% | 0.0% |
| Q2 2023 | $6,249,200 | +1.1% | 173,252 | +7.1% | 0.00% | -33.3% |
| Q1 2023 | $6,180,250 | +55.8% | 161,829 | +132.2% | 0.00% | +50.0% |
| Q4 2022 | $3,966,385 | +88.4% | 69,708 | +31.0% | 0.00% | +100.0% |
| Q3 2022 | $2,105,000 | -74.2% | 53,231 | -71.3% | 0.00% | -66.7% |
| Q2 2022 | $8,174,000 | +141.6% | 185,777 | +119.0% | 0.00% | – |
| Q1 2022 | $3,383,000 | -32.3% | 84,845 | -31.8% | 0.00% | -100.0% |
| Q4 2021 | $5,000,000 | +100.6% | 124,330 | +103.0% | 0.00% | 0.0% |
| Q3 2021 | $2,492,000 | -20.6% | 61,252 | -11.4% | 0.00% | 0.0% |
| Q2 2021 | $3,139,000 | -24.9% | 69,126 | -31.1% | 0.00% | -50.0% |
| Q1 2021 | $4,182,000 | -39.2% | 100,277 | -37.7% | 0.00% | -33.3% |
| Q4 2020 | $6,877,000 | +139.4% | 161,006 | +47.3% | 0.00% | +50.0% |
| Q3 2020 | $2,872,000 | -55.2% | 109,311 | -54.3% | 0.00% | -60.0% |
| Q2 2020 | $6,414,000 | +3367.0% | 239,211 | +2222.4% | 0.01% | – |
| Q1 2020 | $185,000 | -67.8% | 10,300 | -68.2% | 0.00% | -100.0% |
| Q4 2019 | $574,000 | +85.2% | 32,357 | +62.1% | 0.00% | 0.0% |
| Q3 2019 | $310,000 | -31.3% | 19,967 | -28.7% | 0.00% | – |
| Q1 2019 | $451,000 | -26.8% | 27,986 | -17.5% | 0.00% | -100.0% |
| Q3 2018 | $616,000 | +127.3% | 33,920 | +145.3% | 0.00% | 0.0% |
| Q1 2018 | $271,000 | -72.1% | 13,829 | -71.1% | 0.00% | -66.7% |
| Q4 2017 | $970,000 | +17.0% | 47,876 | +0.3% | 0.00% | +50.0% |
| Q3 2017 | $829,000 | +148.9% | 47,747 | +83.6% | 0.00% | +100.0% |
| Q2 2017 | $333,000 | +21.5% | 26,011 | -18.0% | 0.00% | -50.0% |
| Q2 2016 | $274,000 | +35.6% | 31,702 | +48.8% | 0.00% | +100.0% |
| Q1 2016 | $202,000 | +6.9% | 21,305 | +95.5% | 0.00% | 0.0% |
| Q4 2015 | $189,000 | -33.7% | 10,900 | -48.6% | 0.00% | -50.0% |
| Q3 2015 | $285,000 | -83.1% | 21,207 | -71.6% | 0.00% | -81.8% |
| Q2 2015 | $1,683,000 | – | 74,544 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |